title: Recovery from immunosuppression-related disorders in humans and animals by IP-PA1, an edible lipopolysaccharide.
abstract: Immunopotentiator from Pantoea agglomerans 1 (IP-PA1), an edible lipopolysaccharide (LPS) derived from symbiotic bacteria in crops, is a promising immunomodulator. It activates macrophages and protects from chemotherapeutic agent-induced growth inhibition in macrophages in vitro. We showed the immune-recovery effects of IP-PA1 in a chicken model of dexamethasone-induced stress in which IP-PA1 inhibited thymic and bursal atrophy and improved antibody production in response to vaccination. Furthermore, we showed IP-PA1 improved survival of melanoma-bearing, doxorubicin-treated mice, although not directly affecting the proliferation of melanoma cells, dominantly through the improvement of host antitumor immunity. These results suggest that IP-PA1 could have other possible applications in the treatment of various immunosuppression-related disorders in humans and animals.
authors.affiliation: Laboratory of Veterinary Physiology, Division of Animal Life Science, Graduate School, Institute of Symbiotic Science and Technology, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu, Tokyo 183-8509, Japan.
authors.forename: Takehisa
authors.initials: T
authors.lastname: Hebishima
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Gen
authors.initials: G
authors.lastname: Watanabe
authors.forename: Gen-Ichiro
authors.initials: G
authors.lastname: Soma
authors.forename: Chie
authors.initials: C
authors.lastname: Kohchi
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Taya
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Hirota
mesh_terms: D000818:Animals; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D007154:Immune System Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008070:Lipopolysaccharides / Q000627:therapeutic use*; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000503:physiopathology; D013312:Stress, Physiological
chemical_list: D007166:Immunosuppressive Agents; D008070:Lipopolysaccharides; C524847:lipopolysaccharide IP-PA1, Pantoea agglomerans; D003907:Dexamethasone